XBIT XBiotech Inc

Price (delayed)

$1.91

Market cap

$58.23M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.48

Enterprise value

-$51.3M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 4

XBiotech is pioneering the discovery and development of targeted antibodies based on its True Human™ technology. The company’s mission is to rethink the way antibody medicines are discovered and commercialized by ...

Highlights
XBiotech's EPS has shrunk by 61% YoY and by 12% QoQ
XBiotech's net income has plunged by 60% YoY and by 12% from the previous quarter

Key stats

What are the main financial stats of XBIT

XBIT stock price

How has the XBiotech stock price performed over time
Intraday
-3.05%
1 week
-9.91%
1 month
-12.39%
1 year
-22.36%
YTD
-20.08%
QTD
-12.79%

Financial performance

How have XBiotech's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$48.22M
Net income
-$45.13M
Gross margin
N/A
Net margin
N/A
XBiotech's net income has plunged by 60% YoY and by 12% from the previous quarter
The company's operating income fell by 32% YoY

Price vs fundamentals

How does XBIT's price correlate with its fundamentals

Growth

What is XBiotech's growth rate over time

Valuation

What is XBiotech stock price valuation
P/E
N/A
P/B
0.45
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
XBiotech's EPS has shrunk by 61% YoY and by 12% QoQ
The P/B is 33% lower than the 5-year quarterly average of 0.7 and 6% lower than the last 4 quarters average of 0.5
The equity has declined by 26% year-on-year and by 4.9% since the previous quarter

Efficiency

How efficient is XBiotech business performance
XBIT's ROA has shrunk by 108% YoY and by 21% QoQ
The return on equity has dropped by 103% year-on-year and by 21% since the previous quarter
XBIT's ROIC has shrunk by 71% YoY and by 14% QoQ

Dividends

What is XBIT's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history

Special dividends are included in TTM DPS and yield

Financial health

How did XBiotech financials performed over time
The total assets has declined by 25% year-on-year and by 4.4% since the previous quarter
XBIT's quick ratio is down by 18% year-on-year and by 15% since the previous quarter
The debt is 100% lower than the equity
The equity has declined by 26% year-on-year and by 4.9% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.